The Department of Transportation (DOT) recently issued a notice addressing questions about CBD (Cannabidiol) use and its potential impact on federal drug test results. This guidance aims to clarify how consuming CBD products may affect employees in safety-sensitive positions who are subject to DOT drug testing.
CBD vs. Marijuana Testing
The DOT emphasizes that its drug tests do not screen for CBD but rather for marijuana. Hemp-derived products with THC concentrations below 0.3% are not classified as marijuana under federal law. However, before consuming any CBD product, it is crucial to verify its THC concentration level.
Proceed with Caution
The Food and Drug Administration (FDA) does not currently certify the THC content in CBD products, and product labels may be inaccurate. For example, a product labeled as containing 0.25% THC could have a higher concentration. As a result, anyone subject to DOT drug testing must understand the risks associated with using CBD products.
The FDA has issued warnings to companies found misrepresenting CBD product contents, but discrepancies remain. Importantly, if an individual tests positive for THC on a federally regulated drug test, claiming the use of a CBD product will not be considered a valid medical explanation.
Key Takeaway for Safety-Sensitive Employees
Employees in safety-sensitive roles should carefully weigh the risks before using CBD products. Even trace amounts of THC above 0.3% can result in a positive drug test. To ensure compliance and avoid jeopardizing employment, the safest course of action is to refrain from using CBD products altogether.
Learn More
For additional details, you can read the DOT’s full notice here.
